Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine

Clinical and Vaccine Immunology

Volumn 16, Issue 5, 2009, Pages 719-725

  Huang, Joanne ^a   D'Souza, Ajit J ^a   Alarcon, Jason B ^a   Mikszta, John A ^a   Ford, Brandi M ^a   Ferriter, Matthew S ^a   Evans, Michelle ^a   Stewart, Todd ^a   Amemiya, Kei ^b   Ulrich, Robert G ^b   Sullivan, Vincent J ^a  

^a BD Technologies   (United States)

^b US Army Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G; PLAGUE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRY POWDER; FEASIBILITY STUDY; FEMALE; FREEZE DRYING; IMMUNOGENICITY; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FEMALE; FREEZE DRYING; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MICE; PLAGUE; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; POWDERS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; YERSINIA PESTIS;

EID: 66849111906     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00447-08     Document Type: Article

References (42)

1. Alarcon, J. B., A. W. Hartley, N. G. Harvey, and J. A. Mikszta. 2007. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin. Vaccine Immunol. 14:375-381.
2. American Thoracic Society and Centers for Disease Control and Prevention. 2000. Diagnostic standards and classification of tuberculosis in adults and children. Am. J. Respir. Crit. Care Med. 161:1376-1395.
3. Anderson, G. W., Jr., S. E. Leary, E. D. Williamson, R. W. Titball, S. L.Welkos, P. L. Worsham, and A. M. Friedlander. 1996. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect. Immun.64:4580-4585.
4. Anderson, G. W., Jr., P. L. Worsham, C. R. Bolt, G. P. Andrews, S. L.Welkos, A. M. Friedlander, and J. P. Burans. 1997. Protection ofmice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am. J. Trop. Med. Hyg. 56:471-473.
5. Anderson, J., E. Fishbourne, A. Corteyn, and A. I. Donaldson. 2000. Protection of cattle against rinderpest by intranasal immunisation with a dry powder tissue culture vaccine. Vaccine 19:840-843.
6. Andrews, G. P., D. G. Heath, G. W. Anderson, Jr., S. L. Welkos, and A. M.Friedlander. 1996. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect. Immun. 64:2180-2187.
7. Belshe, R. B., F. K. Newman, J. Cannon, C. Duane, J. Treanor, C. VanHoecke, B. J. Howe, and G. Dubin. 2004. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351:2286- 2294.
8. Bryan, J. P., M. H. Sjogren, P. Macarthy, E. Cox, L. J. Legters, and P. L.Perine. 1992. Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose. Vaccine 10:33-38.
9. Burrows, T. W. 1963. Virulence ofPasteurella pestisand immunityto plague. Ergeb. Mikrobiol. Immunitatsforsch. Exp. Ther. 37:59-113.
10. Cohen, R. J., and J. L. Stockard. 1967. Pneumonic plague in an untreated plague-vaccinated individual. JAMA 202:365-366.
11. Cohn, D., and R. J. O'Brien. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb. Mortal. Wkly. Rep. 49:1-54.
12. de Swart, R. L., C. LiCalsi, A. V. Quirk, G. van Amerongen, V. Nodelman, R. Alcock, S. Yuksel, G. H. Ward, J. G. Hardy, H. Vos, C. L. Witham, C. I. Grainger, T. Kuiken, B. J. Greenspan, T. G. Gard, and A. D. Osterhaus. 2007. Measles vaccination of macaques by dry powder inhalation. Vaccine 25:1183-1190.
13. Galimand, M., A. Guiyoule, G. Gerbaud, B. Rasoamanana, S. Chanteau, E. Carniel, and P. Courvalin. 1997. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N. Engl. J. Med. 337:677-680.
14. Heath, D. G., G. W. Anderson, Jr., J. M. Mauro, S. L. Welkos, G. P. Andrews,J. Adamovicz, and A. M. Friedlander. 1998. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16:1131-1137.
15. Hill, J., C. Copse, S. Leary, A. J. Stagg, E. D. Williamson, and R. W. Titball.2003. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect. Immun.71:2234-2238.
16. Hill, J., S. E. Leary, K. F. Griffin, E. D. Williamson, and R. W. Titball. 1997. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect. Immun. 65:4476-4482.
17. Huang, J., R. J. Garmise, T. M. Crowder, K. Mar, C. R. Hwang, A. J. Hickey,J. A. Mikszta, and V. J. Sullivan. 2004. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 23:794-801.
18. Huang, J., J. A. Mikszta, M. S. Ferriter, G. Jiang, N. G. Harvey, B. Dyas,C. J. Roy, R. G. Ulrich, and V. J. Sullivan. 2007. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum. Vaccin. 3:90-93.
19. Illum, L., I. Jabbal-Gill, M. Hinchcliffe, A. N. Fisher, and S. S. Davis. 2001.Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev.51:81-96.
20. Inglesby, T. V., D. T. Dennis, D. A. Henderson, J. G. Bartlett, M. S. Ascher,E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, J. F. Koerner, M. Layton,J. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K.Russell, M. Schoch-Spana, K. Tonat, et al. 2000. Plague as a biological weapon: medical and public health management. JAMA 283:2281-2290.
21. Jiang, G., S. B. Joshi, L. J. Peek, D. T. Brandau, J. Huang, M. S. Ferriter, W. D. Woodley, B. M. Ford, K. D. Mar, J. A. Mikszta, C. R. Hwang, R. Ulrich, N. G. Harvey, C. R. Middaugh, and V. J. Sullivan. 2006. Anthraxvaccine powder formulations for nasal mucosal delivery. J. Pharm. Sci. 95:80-96.
22. Jones, S. M., K. F. Griffin, I. Hodgson, and E. D. Williamson. 2003. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 21:3912-3918.
23. Jones, T., J. J. Adamovicz, S. L. Cyr, C. R. Bolt, N. Bellerose, L. M. Pitt,G. H. Lowell, and D. S. Burt. 2006. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 24:1625-1632.
24. Kenney, R. T., S. A. Frech, L. R. Muenz, C. P. Villar, and G. M. Glenn. 2004. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351:2295-2301.
25. Laurent, P. E., S. Bonnet, P. Alchas, P. Regolini, J. A. Mikszta, R. Pettis, and N. G. Harvey. 2007. Evaluation of the clinical performance of a new intra- dermal vaccine administration technique and associated delivery system. Vaccine 25:8833-8842.
26. Meyer, K. F. 1970. Effectiveness of live or killed plague vaccines in man. Bull. W. H. O. 42:653-666.
27. Mikszta, J. A., J. P. Dekker III, N. G. Harvey, C. H. Dean, J. M. Brittingham, J. Huang, V. J. Sullivan, B. Dyas, C. J. Roy, and R. G. Ulrich. 2006. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. 74:6806-6810.
28. Mikszta, J. A., V. J. Sullivan, C. Dean, A. M. Waterston, J. B. Alarcon, J. P. Dekker III, J. M. Brittingham, J. Huang, C. R. Hwang, M. Ferriter, G. Jiang, K. Mar, K. U. Saikh, B. G. Stiles, C. J. Roy, R. G. Ulrich, and N. G. Harvey. 2005. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191:278-288.
29. Moyle, P. M., and I. Toth. 2008. Self-adjuvanting lipopeptide vaccines. Curr. Med. Chem. 15:506-516.
30. Mueller, C. A., P. Broz, S. A. Muller, P. Ringler, F. Erne-Brand, I. Sorg, M. Kuhn, A. Engel, and G. R. Cornelis. 2005. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 310:674-676.
31. Neutra, M. R., and P. A. Kozlowski. 2006. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6:148-158.
32. Powell, B. S., G. P. Andrews, J. T. Enama, S. Jendrek, C. Bolt, P. Worsham, J. K. Pullen, W. Ribot, H. Hines, L. Smith, D. G. Heath, and J. J. Adamovicz. 2005. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol. Prog. 21:1490-1510.
33. Russell, P., S. M. Eley, S. E. Hibbs, R. J. Manchee, A. J. Stagg, and R. W. Titball. 1995. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13:1551-1556.
34. Sullivan, V. J., J. A. Mikszta, P. Laurent, J. Huang, and B. Ford. 2006. Noninvasive delivery technologies: respiratory delivery of vaccines. Exp. Opin. Drug Deliv. 3:87-95.
35. Uddowla, S., L. C. Freytag, and J. D. Clements. 2007. Effect ofadjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine 25:7984-7993.
36. USAMRIID. 2005. USAMRIID's Medical Management of Biological Casualties Handbook, 6th ed. USAMRIID, Frederick, MD.
37. Warrell, M. J., D. A. Warrell, P. Suntharasamai, C. Viravan, A. Sinhaseni, D. Udomsakdi, R. Phanfung, C. Xueref, J. C. Vincent-Falquet, K. G. Nicholson, D. Bunnag, and T. Harinasuta. 1983. An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis. Lancet ii:301-304.
38. Welkos, S. L., K. M. Davis, L. M. Pitt, P. L. Worsham, and A. M. Freidlander. 1995. Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis. Contrib. Microbiol. Immunol. 13:299-305.
39. Welkos, S. L., A. M. Friedlander, and K. J. Davis. 1997. Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092. Microb. Pathog. 23:211-223.
40. Williamson, E. D. 2001. Plague vaccine research and development. J. Appl. Microbiol. 91:606-608.
41. Williamson, E. D., S. M. Eley, K. F. Griffin, M. Green, P. Russell, S. E.Leary, P. C. Oyston, T. Easterbrook, K. M. Reddin, A. Robinson, et al. 1995.A new improved sub-unit vaccine for plague: the basis of protection. FEMSImmunol. Med. Microbiol. 12:223-230.
42. Williamson, E. D., S. M. Eley, A. J. Stagg, M. Green, P. Russell, and R. W.Titball. 1997. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonicplague. Vaccine 15:1079-1084.